首页> 美国卫生研究院文献>Blood Advances >Cell-surface C-type lectin-like receptor CLEC-1 dampens dendritic cell activation and downstream Th17 responses
【2h】

Cell-surface C-type lectin-like receptor CLEC-1 dampens dendritic cell activation and downstream Th17 responses

机译:细胞表面C型凝集素样受体CLEC-1抑制树突状细胞激活和下游Th17反应。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Dendritic cells (DCs) represent essential antigen-presenting cells that are critical for linking innate and adaptive immunity, and influencing T-cell responses. Among pattern recognition receptors, DCs express C-type lectin receptors triggered by both exogenous and endogenous ligands, therefore dictating pathogen response, and also shaping T-cell immunity. We previously described in rat, the expression of the orphan C-type lectin-like receptor-1 (CLEC-1) by DCs and demonstrated in vitro its inhibitory role in downstream T helper 17 (Th17) activation. In this study, we examined the expression and functionality of CLEC-1 in human DCs, and show a cell-surface expression on the CD16 subpopulation of blood DCs and on monocyte-derived DCs (moDCs). CLEC-1 expression on moDCs is downregulated by inflammatory stimuli and enhanced by transforming growth factor β. Moreover, we demonstrate that CLEC-1 is a functional receptor on human moDCs and that although not modulating the spleen tyrosine kinase-dependent canonical nuclear factor-κB pathway, represses subsequent Th17 responses. Interestingly, a decreased expression of CLEC1A in human lung transplants is predictive of the development of chronic rejection and is associated with a higher level of interleukin 17A (IL17A). Importantly, using CLEC-1–deficient rats, we showed that disruption of CLEC-1 signaling led to an enhanced Il12p40 subunit expression in DCs, and to an exacerbation of downstream in vitro and in vivo CD4+ Th1 and Th17 responses. Collectively, our results establish a role for CLEC-1 as an inhibitory receptor in DCs able to dampen activation and downstream effector Th responses. As a cell-surface receptor, CLEC-1 may represent a useful therapeutic target for modulating T-cell immune responses in a clinical setting.
机译:树突状细胞(DC)代表必需的抗原呈递细胞,对于连接先天免疫和适应性免疫以及影响T细胞反应至关重要。在模式识别受体中,DCs表达由外源和内源性配体触发的C型凝集素受体,因此决定了病原体的反应,并影响了T细胞免疫力。我们先前在大鼠中描述了DC孤儿C型凝集素样受体1(CLEC-1)的表达,并在体外证明了其在下游T辅助17(Th17)激活中的抑制作用。在这项研究中,我们检查了CLEC-1在人DC中的表达和功能,并显示了血DC的CD16 -亚群和单核细胞衍生的DC(moDC)上的细胞表面表达。在moDCs上的CLEC-1表达被炎性刺激下调,并被转化生长因子β增强。此外,我们证明CLEC-1是人类moDCs上的功能性受体,尽管不调节脾酪氨酸激酶依赖性经典核因子κB途径,但可抑制随后的Th17反应。有趣的是,在人肺移植中CLEC1A表达的降低预示着慢性排斥反应的发展,并与白细胞介素17A(IL17A)的升高有关。重要的是,使用缺乏CLEC-1的大鼠,我们发现CLEC-1信号的破坏导致DC中增强的Il12p40亚基表达,并加剧了下游体内和体外CD4 + Th1和Th17回应。总的来说,我们的结果确立了CLEC-1作为DC中抑制受体的作用,该受体能够抑制激活和下游效应子Th反应。作为细胞表面受体,CLEC-1可能代表在临床环境中调节T细胞免疫反应的有用治疗靶标。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号